Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: Extending the age of KCNJ11 mutation testing in neonatal DM

Pediatric Diabetes

Volumn 11, Issue 3, 2010, Pages 203-207

  Mohamadi, Ali ^a   Clark, Loretta M ^a   Lipkin, Paul H ^a   Mahone, E Mark ^a   Wodka, Ericka L ^a   Plotnick, Leslie P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Child development; DEND syndrome; DM, neonatal; Gene mutation

Indexed keywords

C PEPTIDE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; ANTIDIABETIC AGENT; INWARDLY RECTIFYING POTASSIUM CHANNEL;

ADOLESCENT; ARTICLE; BEHAVIOR DISORDER; CASE REPORT; DEND SYNDROME; DEVELOPMENTAL DISORDER; DIABETES MELLITUS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; GENETIC ANALYSIS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MALE; MENTAL DISEASE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; COMPLICATION; DEVELOPMENTAL DISABILITIES; DIABETES MELLITUS, TYPE 1; EPILEPSY; GENETICS; NEWBORN; ORAL DRUG ADMINISTRATION; PATIENT CARE; SUBCUTANEOUS DRUG ADMINISTRATION; SYNDROME; TREATMENT WITHDRAWAL;

ADMINISTRATION, ORAL; ADOLESCENT; CONTINUITY OF PATIENT CARE; DEVELOPMENTAL DISABILITIES; DIABETES MELLITUS, TYPE 1; EPILEPSY; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INFANT, NEWBORN; INFUSIONS, SUBCUTANEOUS; INSULIN; MALE; POTASSIUM CHANNELS, INWARDLY RECTIFYING; SYNDROME; WITHHOLDING TREATMENT;

EID: 77954442715     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2009.00548.x     Document Type: Article

References (15)

1. Sagen JV, Raeder H, Hathout E. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004, 53:2713-2718.
2. Klupa T, Edghill EL, Nazim J. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation. Diabetologia 2005, 48:1029-1031.
3. Zung A, Glaser B, Nimri R, Zadik Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab 2004, 89:5504-5507.
4. Codner E, Flanagan S, Ellard S, Garcia H, Hattersley AT. High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care 2005, 28:758-759.
5. Colombo C, Delvecchio M, Zecchino C, Faienza MF, Cavallo L, Barbetti F. Transient neonatal diabetes mellitus is associated with a recurrent (R201H) KCNJ11 (KIR6.2) mutation. Diabetologia 2005, 48:2439-2441.
6. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic β-cell diabetes. Nat Clin Pract Endocrinol Metab 2008, 4:200-213.
7. Gloyn AL, Pearson ER, Antcliff JF. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004, 350:1838-1849.
8. Slingerland AS, Hattersley AT. Mutations in the Kir6.2 subunit of the KATP channel and permanent neonatal diabetes: new insights and new treatment. Ann Med 2005, 37:186-195.
9. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005, 54:2503-2513.
10. Koster JC, Cadario F, Peruzzi C, Colombo C, Nichols CG, Barbetti F. The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. J Clin Endocrinol Metab 2007, 93:1054-1061.
11. Slingerland AS, Hurkx W, Noordam K. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabet Med 2008, 25:277-281.
12. Mlynarski W, Tarasov AI, Gach A. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nat Clin Pract Neurol 2007, 3:640-645.
13. Slingerland AS, Nuboer R, Hadders-Algra M, Hattersley AT, Bruining GH. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with syndrome of intermediate developmental delay, early-onset generalized epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia 2006, 49:2559-2563.
14. Stoy J, Greeley SAW, Paz VP. Diagnosis and treatment of neonatal diabetes: an United States experience. Pediatr Diabetes 2008, 9:450-459. United States Neonatal Diabetes Working Group
15. Monaghan MC, Stoy J, Streisand R, Philipson L, Cogen FR. Transitioning from insulin to glyburide in permanent neonatal diabetes: medical and psychosocial challenges in an 18-year-old male. Clin Diabetes 2009, 27:25-29.